Target-Specific Imaging and Delivery of siRNA to Tumors
靶标特异性成像和 siRNA 向肿瘤的递送
基本信息
- 批准号:8077381
- 负责人:
- 金额:$ 24.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-13 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:AwardBiological AvailabilityComplexDetectionDevelopmentDyesGoalsImageImaging DeviceImaging TechniquesIn VitroLabelLinkMagnetic ResonanceMagnetic Resonance ImagingMagnetismMalignant NeoplasmsMediatingMembraneMentorsMethodsModelingPeptidesPhaseProcessRNA InterferenceResolutionSmall Interfering RNATherapeuticTherapeutic AgentsTherapeutic EffectTherapeutic StudiesTissueschemotherapyin vivointerestnanoparticlenovel strategiesoptical imagingproduct developmenttherapeutic targettumortumor growthuptake
项目摘要
DESCRIPTION (provided by applicant): With the increased interest in the potential of RNA interference as a therapeutic strategy, novel strategies for siRNA delivery to target tissues are urgently needed. In addition, for a more accurate assessment of the efficacy of the delivery method, non-invasive approaches for detection and tracking of siRNA bioavailability are essential. We have previously described the development of dual-purpose nanoparticle probes for in vivo transfer of synthetic siRNA to tumors and the simultaneous imaging of its accumulation in target tissues by high resolution magnetic resonance and near-infrared optical imaging techniques. These probes consisted of magnetic nanoparticles, labeled with a near-infrared dye, and covalently linked to siRNA molecules specific for model or therapeutic targets. In addition, these nanoparticles were modified with a membrane translocation peptide for intracellular delivery. We demonstrated the feasibility of tracking the in vivo tumor uptake of these complexes by MRI and NIRF imaging in two separate tumor models and also used proof-of- principle optical imaging to corroborate the efficiency of the silencing process. In this proposal, we plan to take this approach to the next level and develop a tumor-targeted imaging and delivery module with the ultimate goal of mediating a therapeutic effect. In the mentored phase of the award, we plan to establish the synthesis and in vitro functionality of our probe. In the independent phase, we will investigate the potential of our tumor-targeted nanoparticle probe, not only as an imaging tool for the assessment of siRNA delivery to tumors, but also as a therapeutic agent capable of inhibiting tumor growth. We will perform therapeutic studies with our probe, alone and in combination with standard chemotherapy, in an attempt to achieve the most significant anti-tumor effects. These studies represent an early step towards exploring the potential of siRNA for tumor therapy. In addition, our planned studies combine imaging and therapeutic agent delivery in a single nanoparticle module, which is essential for cancer therapeutic-product development and optimization.
描述(由申请人提供):随着对RNA干扰作为一种治疗策略的潜力的兴趣增加,迫切需要将siRNA递送到靶组织的新策略。此外,为了更准确地评估递送方法的有效性,检测和跟踪siRNA生物利用度的非侵入性方法是必不可少的。我们之前已经描述了双重用途纳米颗粒探针的发展,用于将合成的siRNA在体内转移到肿瘤中,并通过高分辨率磁共振和近红外光学成像技术同时成像其在靶组织中的积累。这些探针由磁性纳米颗粒组成,用近红外染料标记,并与模型或治疗靶点特异性的siRNA分子共价连接。此外,这些纳米颗粒被膜易位肽修饰,用于细胞内递送。我们在两种不同的肿瘤模型中通过MRI和NIRF成像证明了跟踪这些复合物在体内肿瘤摄取的可行性,并且还使用原理证明光学成像来证实沉默过程的效率。在本提案中,我们计划将这种方法提升到一个新的水平,开发一个肿瘤靶向成像和传递模块,最终目标是介导治疗效果。在该奖项的指导阶段,我们计划建立我们探针的合成和体外功能。在独立阶段,我们将研究我们的肿瘤靶向纳米颗粒探针的潜力,不仅作为评估siRNA向肿瘤传递的成像工具,而且作为能够抑制肿瘤生长的治疗剂。我们将使用我们的探针进行治疗研究,单独或与标准化疗相结合,试图达到最显著的抗肿瘤效果。这些研究为探索siRNA在肿瘤治疗中的潜力迈出了早期的一步。此外,我们计划的研究将成像和治疗剂输送结合在一个纳米颗粒模块中,这对癌症治疗产品的开发和优化至关重要。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Risk stratification of prostate cancer patients based on EPS-urine zinc content.
基于EPS-尿锌含量的前列腺癌患者的风险分层。
- DOI:
- 发表时间:2014
- 期刊:
- 影响因子:5.3
- 作者:Medarova,Zdravka;Ghosh,SubrataK;Vangel,Mark;Drake,Richard;Moore,Anna
- 通讯作者:Moore,Anna
Noninvasive MRI-SERS imaging in living mice using an innately bimodal nanomaterial.
- DOI:10.1021/nn102587h
- 发表时间:2011-02-22
- 期刊:
- 影响因子:17.1
- 作者:Yigit MV;Zhu L;Ifediba MA;Zhang Y;Carr K;Moore A;Medarova Z
- 通讯作者:Medarova Z
Sensing miRNA: Signal Amplification by Cognate RISC for Intracellular Detection of miRNA in Live Cells.
传感 miRNA:通过 Cognate RISC 进行信号放大,用于活细胞中 miRNA 的胞内检测。
- DOI:10.1007/978-1-4939-3148-4_10
- 发表时间:2016
- 期刊:
- 影响因子:0
- 作者:Kavishwar,Amol;Medarova,Zdravka
- 通讯作者:Medarova,Zdravka
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zdravka O Medarova其他文献
Zdravka O Medarova的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zdravka O Medarova', 18)}}的其他基金
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer
转移性乳腺癌一流疗法的临床开发
- 批准号:
10596292 - 财政年份:2021
- 资助金额:
$ 24.15万 - 项目类别:
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer
转移性乳腺癌一流疗法的临床开发
- 批准号:
10631223 - 财政年份:2021
- 资助金额:
$ 24.15万 - 项目类别:
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer
MicroRNA 治疗淋巴结转移性乳腺癌
- 批准号:
8367166 - 财政年份:2012
- 资助金额:
$ 24.15万 - 项目类别:
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer
MicroRNA 治疗淋巴结转移性乳腺癌
- 批准号:
8530182 - 财政年份:2012
- 资助金额:
$ 24.15万 - 项目类别:
Target-Specific Imaging and Delivery of siRNA to Tumors
靶标特异性成像和 siRNA 向肿瘤的递送
- 批准号:
7849163 - 财政年份:2007
- 资助金额:
$ 24.15万 - 项目类别:
Target-Specific Imaging and Delivery of siRNA to Tumors
靶标特异性成像和 siRNA 向肿瘤的递送
- 批准号:
7893114 - 财政年份:2007
- 资助金额:
$ 24.15万 - 项目类别:
Target-Specific Imaging and Delivery of siRNA to Tumors
靶标特异性成像和 siRNA 向肿瘤的递送
- 批准号:
7301141 - 财政年份:2007
- 资助金额:
$ 24.15万 - 项目类别:
Target-Specific Imaging and Delivery of siRNA to Tumors
靶标特异性成像和 siRNA 向肿瘤的递送
- 批准号:
7469587 - 财政年份:2007
- 资助金额:
$ 24.15万 - 项目类别:
相似海外基金
Nutrient bioavailability and metal toxicity with a focus on the influence of geochemical parameters on the biological availability of trace metals
营养物生物利用度和金属毒性,重点关注地球化学参数对微量金属生物利用度的影响
- 批准号:
346752-2007 - 财政年份:2007
- 资助金额:
$ 24.15万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
SGER: Development of a Reporter System Regulated by the Biological Availability of Fe in Saltwater
SGER:开发由盐水中铁的生物有效性调节的报告系统
- 批准号:
0002968 - 财政年份:2000
- 资助金额:
$ 24.15万 - 项目类别:
Standard Grant
Pollutants in sediments and their environmental impact, esp speciation and biological availability of metals
沉积物中的污染物及其环境影响,特别是金属的形态和生物有效性
- 批准号:
5555510-1995 - 财政年份:1995
- 资助金额:
$ 24.15万 - 项目类别:
Bilateral Exchange Program (H)
Iron Speciation and Its Biological Availability in Seawater: A Workshop
海水中铁形态及其生物有效性:研讨会
- 批准号:
9314179 - 财政年份:1994
- 资助金额:
$ 24.15万 - 项目类别:
Standard Grant
Biological availability of amino acids from Canadian fish meals and fish silage in Atlantic salmo diets
大西洋鲑日粮中加拿大鱼粉和鱼青贮饲料中氨基酸的生物利用度
- 批准号:
45874-1989 - 财政年份:1991
- 资助金额:
$ 24.15万 - 项目类别:
Collaborative Research and Development Grants - Government (H)
Marine Humic Substances: Formation Via Vascular Plant Degradation and Biological Availability
海洋腐殖质:通过维管植物降解和生物利用度形成
- 批准号:
9116450 - 财政年份:1991
- 资助金额:
$ 24.15万 - 项目类别:
Continuing Grant
Special Foreign Currency Award (Including 3,900 Egyptian POunds) For Study of Some Factors Affecting Biological Availability of Drugs
影响药物生物利用度的部分因素研究特别外币奖(含3,900埃及镑)
- 批准号:
7310592 - 财政年份:1973
- 资助金额:
$ 24.15万 - 项目类别:
Standard Grant














{{item.name}}会员




